A growing body of observational research suggests that popular weight-loss drugs known as GLP-1 receptor agonists, including Ozempic and Wegovy, may help reduce the risk of certain cancers. The findings were discussed at a recent conference of cancer specialists, where multiple studies pointed to potential benefits beyond those expected from weight loss alone. These medications are now taken by approximately one in eight American adults.
The research comes primarily from observational studies rather than randomized clinical trials, meaning researchers identified patterns but cannot yet confirm direct causation. One analysis from the University of Pennsylvania found that women between the ages of 45 and 80 who were taking GLP-1 drugs were approximately 30 percent less likely to develop breast cancer compared with those not taking the medications. Another study surveying patients with seven types of early-stage cancer found that GLP-1s significantly reduced the risk of cancer spread in four of them: lung, breast, colon, and liver cancers.
What the Left Is Saying
Progressive health policy advocates are pointing to this research as a potential turning point in addressing obesity-related cancers. Dr. Neil Iyengar, director of breast oncology and cancer survivorship at the Winship Cancer Institute at Emory University, noted that one in seven male cancer-related deaths and one in six female cancer-related deaths are linked to obesity. He described the data as potentially representing 'a massive possible shift in the global health burden' if GLP-1 medications prove effective in broader populations.
Patient advocacy groups have argued that if these findings hold up in clinical trials, insurance companies and public programs like Medicare should cover GLP-1s for cancer prevention purposes, not just diabetes and weight management. The American Cancer Society has long called for policies that address obesity as a cancer risk factor, and some advocates say expanded drug coverage could align with existing prevention strategies.
What the Right Is Saying
Conservative health policy commentators have urged caution, noting that these results come from observational studies that cannot establish causation. They point out that GLP-1 drugs can cost $900 or more per month without insurance coverage, raising questions about the financial implications of expanding their use for cancer prevention purposes.
Some fiscal conservatives have argued that before any policy changes occur, rigorous clinical trials must confirm the benefits. Representative fiscal hawks in Congress have previously raised concerns about the budget impact of covering GLP-1s under federal health programs. Others have emphasized the importance of lifestyle interventions and personal responsibility alongside any pharmacological approach to addressing obesity-related health risks.
What the Numbers Show
Obesity is associated with an increased risk of at least 13 different cancers, according to longstanding research from the National Cancer Institute, with some studies suggesting the number could be as high as 20. GLP-1 receptor agonists typically induce 15 to 20 percent or greater weight loss in patients, similar to amounts achieved through bariatric surgery. The University of Pennsylvania analysis found a roughly 30 percent reduction in breast cancer risk among women taking GLP-1s compared to those not on the medications. The study examining cancer recurrence found significant reductions in disease spread for lung, breast, colon, and liver cancers specifically.
Dr. Iyengar noted that prior research using diet or exercise-induced weight loss showed some reduction in obesity-related cancer risk, though at lower levels than what GLP-1s can achieve. Bariatric surgery studies have demonstrated that greater amounts of induced weight loss correspond to lower cancer risk, providing context for how pharmaceutical weight loss might similarly affect outcomes.
The Bottom Line
Researchers emphasize that while these observational findings are promising, they represent hypotheses requiring confirmation through prospective clinical trials. Dr. Iyengar cautioned that there is still unknown data regarding how GLP-1s may interact with active cancer therapies such as chemotherapy or immunotherapy, and he advised patients currently undergoing treatment to discuss any potential use with their oncologists before starting the medications.
For policymakers, the research raises questions about whether expanded insurance coverage for GLP-1s could be justified on public health grounds if clinical trials confirm cancer prevention benefits. The financial cost of widespread drug coverage would need to be weighed against potential long-term savings in cancer treatment costs. What happens next will likely depend on results from more rigorous studies expected over the coming years.